PE20201202A1 - Inhibidores de cinasa dependientes de ciclina - Google Patents

Inhibidores de cinasa dependientes de ciclina

Info

Publication number
PE20201202A1
PE20201202A1 PE2020001635A PE2020001635A PE20201202A1 PE 20201202 A1 PE20201202 A1 PE 20201202A1 PE 2020001635 A PE2020001635 A PE 2020001635A PE 2020001635 A PE2020001635 A PE 2020001635A PE 20201202 A1 PE20201202 A1 PE 20201202A1
Authority
PE
Peru
Prior art keywords
alkyl
fluoroalkyl
cycline
kinase inhibitors
dependent kinase
Prior art date
Application number
PE2020001635A
Other languages
English (en)
Inventor
Ping Chen
Sujin Cho-Schultz
Judith Gail Deal
Gary Michael Gallego
Mehran Jalaie
Robert Steven Kania
Sajiv Krishnan Nair
Sacha Ninkovic
Suvi Tuula Marjukka Orr
Cynthia Louise Palmer
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of PE20201202A1 publication Critical patent/PE20201202A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Abstract

La presente invencion se refiere a un compuesto de la formula (X) o formula (IX), donde: R1 es H, F, Cl, CN, entre otros; R2 es H, alquilo C1-C5, fluoroalquilo C1-C5, entre otros; R4 es H, alquilo C1-C4, fluoroalquilo C1-C4, entre otros; R6 es H, F, Cl, CN, CH3, entre otros; R7 y R8 son independientemente H, F, Cl, CN, alquilo C1-C2, entre otros; R9 es H, OH, NH2, NHCH3 o N(CH3)2; R10 es independientemente F, CN, alquilo C1-C2 o fluoroalquilo C1-C2; R11 es H, alquilo C1-C4, fluoroalquilo C1-C4, entre otros; n es 0 a 4. Son compuestos especificos: i) 1,5-anhidro-3-({5-cloro-4-[4-fluoro-2-(2-hidroxipropan-2-il)-1-(propan-2-il)-1H-benzimidazol-6-il]-pirimidin-2-il}amino)-2,3-didesoxi-D-treo-pentitol; ii) (3R, 4R)-4-[(5-cloro-4-{4-fluoro-2-[(1R)-1-hidroxietil]-1-(propan-2-il)-1H-benzimidazol-6-il}-pirimidin-2-il)amino]-1-(metasulfonil)piperidin-3-ol. Tambien se refiere a una composicion farmaceutica que los comprende. Dichos compuestos son inhibidores de las cinasas dependientes de ciclina (CDK), siendo utiles en el tratamiento del cancer.
PE2020001635A 2018-04-26 2019-04-22 Inhibidores de cinasa dependientes de ciclina PE20201202A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862663096P 2018-04-26 2018-04-26
US201862750454P 2018-10-25 2018-10-25
US201962826609P 2019-03-29 2019-03-29
PCT/IB2019/053314 WO2019207463A1 (en) 2018-04-26 2019-04-22 2-amino-pyridine or 2-amino-pyrimidine derivatives as cyclin dependent kinase inhibitors

Publications (1)

Publication Number Publication Date
PE20201202A1 true PE20201202A1 (es) 2020-11-11

Family

ID=66676856

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2020001635A PE20201202A1 (es) 2018-04-26 2019-04-22 Inhibidores de cinasa dependientes de ciclina

Country Status (28)

Country Link
US (3) US10766884B2 (es)
EP (1) EP3784664A1 (es)
JP (2) JP7089061B2 (es)
KR (1) KR102596598B1 (es)
CN (1) CN112313219B (es)
AU (1) AU2019259653B2 (es)
BR (1) BR112020021689B1 (es)
CA (1) CA3098283C (es)
CL (1) CL2020002748A1 (es)
CO (1) CO2020013149A2 (es)
CR (1) CR20200503A (es)
CU (1) CU20200070A7 (es)
DO (1) DOP2020000191A (es)
EC (1) ECSP20067394A (es)
GE (1) GEP20227433B (es)
IL (1) IL278075B2 (es)
MA (1) MA52360A (es)
MX (1) MX2020011294A (es)
NI (1) NI202000072A (es)
PE (1) PE20201202A1 (es)
PH (1) PH12020551692A1 (es)
RU (1) RU2762557C1 (es)
SG (1) SG11202009992VA (es)
TW (1) TWI740135B (es)
UA (1) UA126177C2 (es)
UY (1) UY38196A (es)
WO (1) WO2019207463A1 (es)
ZA (1) ZA202006944B (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR109595A1 (es) 2016-09-09 2018-12-26 Incyte Corp Compuestos de pirazolopirimidina y usos de estos como inhibidores de hpk1
US20180072718A1 (en) 2016-09-09 2018-03-15 Incyte Corporation Pyrazolopyridine compounds and uses thereof
CN109923114B (zh) 2016-09-09 2022-11-01 因赛特公司 作为hpk1调节剂的吡唑并吡啶衍生物和其用于治疗癌症的用途
MX2020008656A (es) 2018-02-20 2020-12-09 Incyte Corp Derivados de n-(fenil)-2-(fenil)pirimidina-4-carboxamida y compuestos relacionados como inhibidores de la cinasa de progenitores hematopoyeticos 1 (hpk1) para tratar el cancer.
US10752635B2 (en) 2018-02-20 2020-08-25 Incyte Corporation Indazole compounds and uses thereof
SG11202009992VA (en) 2018-04-26 2020-11-27 Pfizer 2-amino-pyridine or 2-amino-pyrimidine derivatives as cyclin dependent kinase inhibitors
US10899755B2 (en) 2018-08-08 2021-01-26 Incyte Corporation Benzothiazole compounds and uses thereof
US11066404B2 (en) 2018-10-11 2021-07-20 Incyte Corporation Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
US11384083B2 (en) 2019-02-15 2022-07-12 Incyte Corporation Substituted spiro[cyclopropane-1,5′-pyrrolo[2,3-d]pyrimidin]-6′(7′h)-ones as CDK2 inhibitors
US11472791B2 (en) 2019-03-05 2022-10-18 Incyte Corporation Pyrazolyl pyrimidinylamine compounds as CDK2 inhibitors
US11919904B2 (en) 2019-03-29 2024-03-05 Incyte Corporation Sulfonylamide compounds as CDK2 inhibitors
US11447494B2 (en) 2019-05-01 2022-09-20 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
US11440914B2 (en) 2019-05-01 2022-09-13 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
KR20220059480A (ko) 2019-08-06 2022-05-10 인사이트 코포레이션 고체 형태의 hpk1 억제제
KR20220064369A (ko) 2019-08-14 2022-05-18 인사이트 코포레이션 Cdk2 저해제로서의 이미다졸릴 피리디미딘일아민 화합물
US11038699B2 (en) 2019-08-29 2021-06-15 Advanced New Technologies Co., Ltd. Method and apparatus for performing multi-party secure computing based-on issuing certificate
CA3157681A1 (en) 2019-10-11 2021-04-15 Incyte Corporation Bicyclic amines as cdk2 inhibitors
EP4181920A1 (en) 2020-07-15 2023-05-24 Pfizer Inc. Kat6 inhibitor methods and combinations for cancer treatment
IL300581A (en) 2020-08-13 2023-04-01 Pfizer Combined treatment
CN112028834B (zh) * 2020-09-11 2022-03-29 济南悟通生物科技有限公司 一种阿贝西利的中间体的合成方法
CA3195063A1 (en) * 2020-09-15 2022-03-24 Pfizer Inc. Solid forms of a cdk4 inhibitor
CN112679522B (zh) * 2020-12-29 2023-02-14 南京正济医药研究有限公司 一种巴洛沙韦中间体的制备方法
WO2022149057A1 (en) * 2021-01-05 2022-07-14 Rhizen Pharmaceuticals Ag Cdk inhibitors
EP4289848A1 (en) 2021-02-03 2023-12-13 Tuojie Biotech (Shanghai) Co., Ltd. Fused tricyclic cyclin-dependent kinase inhibitor, and preparation method therefor and pharmaceutical use thereof
WO2023100134A1 (en) 2021-12-02 2023-06-08 Pfizer Inc. Methods and dosing regimens comprising a cdk2 inhibitor and a cdk4 inhibitor for treating cancer
WO2023100070A1 (en) 2021-12-02 2023-06-08 Pfizer Inc. Cdk4 inhibitor for the treatment of cancer
WO2023116862A1 (zh) * 2021-12-24 2023-06-29 江苏恒瑞医药股份有限公司 氢化吲哚类化合物、其制备方法及其在医药上的应用
WO2024022487A1 (en) * 2022-07-29 2024-02-01 Allorion Therapeutics Inc Aminoheteroaryl kinase inhibitors
WO2024023703A1 (en) 2022-07-29 2024-02-01 Pfizer Inc. Dosing regimens comprising a kat6 inhibitor for the treatment of cancer
WO2024027631A1 (zh) * 2022-08-01 2024-02-08 江苏恒瑞医药股份有限公司 一种稠三环类衍生物的晶型及制备方法
WO2024051702A1 (zh) * 2022-09-05 2024-03-14 浙江同源康医药股份有限公司 用作cdk4激酶抑制剂的化合物及其应用
WO2024066986A1 (zh) * 2022-09-30 2024-04-04 楚浦创制（武汉）医药科技有限公司 2-氨基嘧啶类化合物及其应用、药用组合物

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
WO2000035296A1 (en) 1996-11-27 2000-06-22 Wm. Wrigley Jr. Company Improved release of medicament active agents from a chewing gum coating
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
BR0014078A (pt) 1999-09-17 2002-12-31 Millennium Pharm Inc Inibidores de fator xa
WO2001064642A2 (en) 2000-02-29 2001-09-07 Cor Therapeutics, Inc. Benzamides and related inhibitors of factor xa
WO2002102783A1 (en) 2001-06-19 2002-12-27 Merck & Co., Inc. Tyrosine kinase inhibitors
GB0308466D0 (en) 2003-04-11 2003-05-21 Novartis Ag Organic compounds
KR101204247B1 (ko) 2003-07-22 2012-11-22 아스텍스 테라퓨틱스 리미티드 3,4-이치환된 1ｈ-피라졸 화합물 및 그의 시클린 의존성키나제 (ｃｄｋ) 및 글리코겐 합성효소 키나제-3(ｇｓｋ-3) 조정제로서 용도
GB0317127D0 (en) * 2003-07-22 2003-08-27 Astex Technology Ltd Pharmaceutical compounds
WO2006038001A1 (en) 2004-10-06 2006-04-13 Celltech R & D Limited Aminopyrimidine derivatives as jnk inhibitors
KR20090040478A (ko) 2006-08-24 2009-04-24 노파르티스 아게 ２-(피라진-２-일)-티아졸 및 ２-(１Ｈ-피라졸-３-일)-티아졸 유도체, 및 대사, 심혈관 및 기타 장애의 치료를 위한 스테아로일-ＣｏＡ 데새투라제(ＳＣＤ) 억제제로서의 관련 화합물
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
KR101892989B1 (ko) 2008-06-27 2018-08-30 셀젠 카르 엘엘씨 헤테로아릴 화합물 및 이의 용도
JP2012512822A (ja) 2008-12-19 2012-06-07 エフ．ホフマン−ラ ロシュ アーゲー ピリミジン−２−イルアミノ誘導体および炎症を治療するためのその使用
PA8852901A1 (es) 2008-12-22 2010-07-27 Lilly Co Eli Inhibidores de proteina cinasa
BR112012005382A2 (pt) 2009-09-10 2016-03-29 Hoffmann La Roche inibidores de jak
CA2798325A1 (en) 2010-05-13 2011-11-17 Amgen Inc. Heteroaryloxyheterocyclyl compounds as pde10 inhibitors
US9464065B2 (en) 2011-03-24 2016-10-11 The Scripps Research Institute Compounds and methods for inducing chondrogenesis
JO3300B1 (ar) 2012-06-06 2018-09-16 Novartis Ag مركبات وتركيبات لتعديل نشاط egfr
CN105189481A (zh) * 2013-03-13 2015-12-23 艾伯维公司 吡啶cdk9激酶抑制剂
EP3039015B1 (en) 2013-08-30 2019-10-30 PTC Therapeutics, Inc. Substituted pyrimidine bmi-1 inhibitors
EP3057954A2 (en) 2013-10-18 2016-08-24 Syros Pharmaceuticals, Inc. Heteromaromatic compounds useful for the treatment of proliferative diseases
MX370906B (es) 2013-12-30 2020-01-09 Genentech Inc Inhibidores de serina/treonina cinasa.
CA2944669A1 (en) 2014-04-04 2015-10-08 Syros Pharmaceuticals, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
US9878994B2 (en) 2014-07-24 2018-01-30 Beta Pharma Inc. 2-H-indazole derivatives as cyclin-dependent kinase (CDK) inhibitors and therapeutic uses thereof
WO2016015604A1 (en) 2014-07-26 2016-02-04 Sunshine Lake Pharma Co., Ltd. Compounds as cdk small-molecule inhibitors and uses thereof
WO2016105118A2 (ko) 2014-12-24 2016-06-30 주식회사 엘지생명과학 Gpr120 효능제로서의 바이아릴 유도체
WO2016192630A1 (zh) 2015-06-01 2016-12-08 中国科学院上海药物研究所 一类具有激酶抑制活性的化合物、制备方法和用途
WO2016210296A1 (en) 2015-06-26 2016-12-29 Dana-Farber Cancer Institute, Inc. 4,6-pyrimidinylene derivatives and uses thereof
CN105111191B (zh) * 2015-07-21 2018-06-08 上海皓元生物医药科技有限公司 一种用于合成cdk9抑制剂的关键中间体及其制备方法和用途
CN106928216A (zh) 2015-12-31 2017-07-07 中国科学院上海药物研究所 具有erk激酶抑制活性的化合物、其制备方法和用途
CN108602799B (zh) 2016-02-06 2021-08-03 上海复尚慧创医药研究有限公司 一类激酶抑制剂
KR102587758B1 (ko) * 2016-07-13 2023-10-12 사이로스 파마수티컬스, 인크. 시클린-의존성 키나제 7 (cdk7)의 억제제
WO2018161033A1 (en) 2017-03-02 2018-09-07 Wright, Adrian Small molecule ire1-alpha inhibitors
US11266640B2 (en) 2017-09-20 2022-03-08 Hangzhou Innogate Pharma Co., Ltd. Polycyclic compound acting as IDO inhibitor and/or IDO-HDAC dual inhibitor
SG11202009992VA (en) 2018-04-26 2020-11-27 Pfizer 2-amino-pyridine or 2-amino-pyrimidine derivatives as cyclin dependent kinase inhibitors

Also Published As

Publication number Publication date
KR20210002642A (ko) 2021-01-08
CU20200070A7 (es) 2021-05-12
RU2762557C1 (ru) 2021-12-21
TW202000661A (zh) 2020-01-01
CA3098283C (en) 2023-05-23
TWI740135B (zh) 2021-09-21
ECSP20067394A (es) 2020-12-31
MA52360A (fr) 2021-03-03
JP7089061B2 (ja) 2022-06-21
IL278075B1 (en) 2023-01-01
US20190330196A1 (en) 2019-10-31
CN112313219B (zh) 2024-04-26
CN112313219A (zh) 2021-02-02
AU2019259653A1 (en) 2020-10-29
US11220494B2 (en) 2022-01-11
KR102596598B1 (ko) 2023-11-03
WO2019207463A1 (en) 2019-10-31
CL2020002748A1 (es) 2021-02-12
BR112020021689A2 (pt) 2021-01-26
DOP2020000191A (es) 2021-02-28
CA3098283A1 (en) 2019-10-31
NI202000072A (es) 2021-03-23
UA126177C2 (uk) 2022-08-25
US20200354350A1 (en) 2020-11-12
KR20230152182A (ko) 2023-11-02
ZA202006944B (en) 2023-07-26
BR112020021689B1 (pt) 2023-02-28
PH12020551692A1 (en) 2021-07-19
US10766884B2 (en) 2020-09-08
SG11202009992VA (en) 2020-11-27
UY38196A (es) 2019-11-29
JP2021522275A (ja) 2021-08-30
AU2019259653B2 (en) 2023-01-19
IL278075B2 (en) 2023-05-01
CO2020013149A2 (es) 2020-11-10
US20220089580A1 (en) 2022-03-24
CR20200503A (es) 2020-12-17
GEP20227433B (en) 2022-10-25
IL278075A (en) 2020-11-30
EP3784664A1 (en) 2021-03-03
JP2022120096A (ja) 2022-08-17
MX2020011294A (es) 2020-11-18
RU2021136543A (ru) 2021-12-16

Similar Documents

Publication Publication Date Title
PE20201202A1 (es) Inhibidores de cinasa dependientes de ciclina
CL2021002965A1 (es) Compuestos antivirales que contienen nitrilo.
PE20191541A1 (es) Composiciones y metodos para inhibir la accion de la arginasa
PE20171241A1 (es) Terapias de combinacion para el tratamiento de canceres
PE20231207A1 (es) Derivados indolicos como inhibidores de ras en el tratamiento del cancer
HN2011000699A (es) El compuesto (s)-1-({4-metil-5-[2-(2,2,2-trifluoro-1,1-dimetil-etil)-piridin-4-il]-tiazol-2-il}-amida) de 2-amida del acido pirrolidin-1,2-dicarboxilico en forma libre o de sal y composiciones y composicion farmaceutica que lo contiene.
PE20210373A1 (es) Compuestos de pirimidina y composiciones farmaceuticas para prevenir o tratar canceres que incluyen los mismos
PE20210392A1 (es) Compuestos utiles para inhibir a cdk7
UY39027A (es) Uso de favipiravir en el tratamiento de la infección por coronavirus
UY36371A (es) Compuestos de indolcarboxamida inhibidores de quinasas tipo btk y tipo tec
AR116115A1 (es) Dimetil amino azetidina amidas como inhibidores de jak
PE20071114A1 (es) Compuestos de tiazol como agentes moduladores de pkb
PA8631201A1 (es) Compuestos de metil-aril o heteroaril-amida sustituida
UY31384A1 (es) Novedosos compuestos heterociclicos para la inhibicion de la proteina quinasa b
PE20201256A1 (es) Compuestos monobactamicos cromanos para el tratamiento de infecciones bacterianas
CO2019004978A2 (es) Compuestos terapéuticos y métodos para utilizarlos
AR125425A1 (es) Inhibidores de proteina tirosina fosfatasa y sus metodos de uso
PE20181017A1 (es) Compuestos heteroarilo y su uso como farmacos terapeuticos
PE20210478A1 (es) Compuestos heteroaromaticos como inhibidores de vanina
MX2019005706A (es) Inhibidores de la tirosina quinasa de bruton.
CL2021001388A1 (es) Compuestos útiles en la terapia para el vih
CL2020002697A1 (es) Moduladores alostéricos positivos del receptor de dopamina d1
CO2021002940A2 (es) Pirazoles fungicidas sustituidos con nitroanilino
CL2022001892A1 (es) Amidas fungicidas
AR048326A1 (es) Derivados de prolinilo